Bain Capital Life Sciences Investors’s SpringWorks Therapeutics SWTX Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,081,307	Closed	-$71.2M	–	30
2023 Q3	$71.2M	Hold	3,081,307	–	–	7.97%	4
2023 Q2	$80.8M	Hold	3,081,307	–	–	8.32%	3
2023 Q1	$79.3M	Sell	3,081,307 -1,750,000	-36%	-$51.1M	9.91%	3
2022 Q4	$126M	Hold	4,831,307	–	–	14.04%	1
2022 Q3	$138M	Hold	4,831,307	–	–	16.45%	1
2022 Q2	$119M	Hold	4,831,307	–	–	13.95%	1
2022 Q1	$273M	Hold	4,831,307	–	–	26.48%	1
2021 Q4	$299M	Hold	4,831,307	–	–	23.75%	1
2021 Q3	$306M	Sell	4,831,307 -1,000,000	-17%	-$77.1M	19.01%	1
2021 Q2	$481M	Hold	5,831,307	–	–	31.49%	1
2021 Q1	$429M	Sell	5,831,307 -1,450,000	-20%	-$114M	24.3%	1
2020 Q4	$528M	Hold	7,281,307	–	–	33.15%	1
2020 Q3	$347M	Hold	7,281,307	–	–	32.35%	1
2020 Q2	$306M	Hold	7,281,307	–	–	32.03%	1
2020 Q1	$197M	Hold	7,281,307	–	–	33.25%	1
2019 Q4	$280M	Hold	7,281,307	–	–	41.8%	1
2019 Q3	$158M	Buy	+7,281,307	New	+$172M	40.64%	1

Other funds holding SWTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bain Capital Life Sciences Investors's SWTX Position: Q4 2023 in Review

Bain Capital Life Sciences Investors sold out of SpringWorks Therapeutics (SWTX) in Q4 2023, closing a stake of 3,081,307 shares — an estimated $71.2M sold.

Bain Capital Life Sciences Investors first reported a position in SWTX in Q3 2019 and held it in 17 quarters. The position peaked at $528M in Q4 2020. 180 funds tracked by Wall St. Rank hold SWTX as of Q4 2023.

Bain Capital Life Sciences Investors reported no remaining SpringWorks Therapeutics position as of Q4 2023 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 3,081,307 SpringWorks Therapeutics shares in Q4 2023, an estimated $71.2M.
Bain Capital Life Sciences Investors first reported a position in SpringWorks Therapeutics in Q3 2019 and held it in 17 quarters.
Bain Capital Life Sciences Investors's SpringWorks Therapeutics position peaked at $528M in Q4 2020.
180 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2023.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2023, filed 13 Feb 2024.